A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Recruiting now · Phase 2

Conditions studied: Crohn's Disease, Ulcerative Colitis

In brief

Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461), TAK-279-UC-2001 (NCT06254950) and TAK-279-CD-2003 (NCT07403968). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able to continue to benefit from the treatment in this study. The main aim of this study is to find out how safe TAK-279 is for long term use and to check if it reduces bowel inflammation and symptoms when used for a longer period of time in adults with moderately to severely active UC or CD. The participants will be treated with TAK-279 for up to 3 years (156 weeks). During the study, participants will visit their study clinic around 15 times.

Key facts

Study ID

NCT06764615

Run by

Takeda

People needed

192

Starts

2025-05-28

Expected to finish

2029-12-30

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant is willing and able to understand and fully comply with trial procedures and requirements (including digital tools and applications), in the opinion of the investigator.
• The participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent form [ICF]) and any required privacy authorization prior to the initiation of any trial procedures.
• Completion of Week 52 in the parent trials (phase 2b CD and phase 2 UC) with valid electronic (e) Diary data for Week 52 (TAK-279-CD-2001 and TAK-279-UC-2001).
• Clinical or symptomatic responder at parent trial Week 52 as defined below:
• TAK-279-CD-2001: Clinical response at Week 52 of the parent trial based on PRO2, assessed as >=30% decrease in average daily very soft or liquid stools and/ or >=30% decrease in average AP from parent trial baseline.
• TAK-279-UC-2001: Symptomatic response at Week 52 of the parent trial, assessed as a reduction in partial modified Mayo score (pmMS) of >=1 points and >=30% from parent trial baseline; and a decrease from parent trial baseline in the rectal bleeding sub-score of >=1 point or an absolute rectal bleeding sub-score of <=1 point.
• TAK-279-CD-2003: Endoscopic response at Week 12 of the parent trial, assessed as a participant achieving decrease in SES-CD >50% from baseline (or for participants with isolated ileal disease, SES-CD <=4 or at least a 2-point reduction from baseline).
• Other General Inclusion Criteria:
• Participants must meet the contraception recommendations.

You may not qualify if…

• Participant considered by the investigator to be unsuitable for the OLE trial due to their trial compliance and medication adherence concerns.
• Participants with malignancy or dysplasia per endoscopy any time during the parent trial or at the beginning of the OLE.
• Exclusion Criteria related to Laboratory Investigations:
• Participants meeting the exclusion criteria related to laboratory investigations as defined in the protocol.
• Exclusion criteria related to other prohibited concomitant medication for TAK-279-CD-2001 and TAK-279-UC-2001 Cohorts:
• Participants taking oral corticosteroids for CD or UC during parent trial at or after Week 48.

Where it is running

• Woodholme Gastroenterology Associates — Glen Burnie, Maryland, United States (enrolling)
• Tyler Research Institute, LLC — Tyler, Texas, United States (enrolling)
• Chongqing General Hospital — Chongqing, Chongqing Municipality, China (enrolling)
• The First Affiliated Hospital of Sun Yat-sen University — Guangdong, Guangdong, China (enrolling)
• The Sixth Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
• Renji Hospital Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
• Hepato-Gastroenterologie HK s.r.o. — Hradec Králové, Czechia (enrolling)
• Pannonia Maganorvosi Centrum — Budapest, Hungary (enrolling)
• St. Antonius Ziekenhuis — Tilburg, North Brabant, Netherlands (enrolling)
• Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj — Torun, Kuyavian-Pomeranian Voivodeship, Poland (enrolling)
• Centrum Medyczne MedykSp. z o.o. Sp. K. — Lublin, Poland (enrolling)
• Twoja Przychodnia - Szczecinskie Centrum Medyczne — Szczecin, Poland (enrolling)
• WIP Warsaw IBD Point Profesor Kierkus — Warsaw, Poland (enrolling)
• Endomed — Košice, Slovakia (enrolling)
• Inje University Haeundae Paik Hospital — Haeundae, Busan Gwangyeogsi, South Korea (enrolling)
• Yonsei University Wonju Severance Christian Hospital — Wŏnju, Gangwon-do, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.